Premium
Wilms’ tumor 1 enhances Cisplatin‐resistance of advanced NSCLC
Author(s) -
Wu Chen,
Wang Yonggong,
Xia Yang,
He Shaohua,
Wang Zhiqiang,
Chen Yijiang,
Wu Changping,
Shu Yongqian,
Jiang Jingting
Publication year - 2014
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2014.10.026
Subject(s) - cisplatin , wilms' tumor , oncogene , cancer research , lung cancer , medicine , oncology , cancer , chemotherapy , cell cycle
Wilms’ tumor 1 ( WT1 ) is an oncogene that has been correlated with tumor progression, bad prognosis and chemo‐resistance in Non‐Small‐Cell lung cancer (NSCLC). Here, we found that WT1 expression is significantly higher in NSCLCs than in benign controls, and that Cisplatin‐resistant patients display a notable increase in WT1 expression following relapse. In vitro, WT1 levels were associated with the IC50 of NSCLC cells and increased along with treatment time and dose of Cisplatin. Furthermore, WT1 enhanced Major Vault Protein ( MVP ) transcription via binding to its promoter. Therefore, WT1 may be a potential therapeutic target for solving resistance.